Mural Oncology Plc (MURA) AI Stock Analysis

• Market Cap: $44.21M
• Dividend Yield: N/A
• Average Volume (3M): 176.39K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.31
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 116
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -1.93
• Shares Outstanding: 17,268,880
• 10 Day Avg. Volume: 86,480
• 30 Day Avg. Volume: 176,392
• PEG Ratio: -0.02
• Price to Book (P/B): -2.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.36
• Enterprise Value/Market Cap: 2.31
• Enterprise Value/Revenue: 19.52
• Enterprise Value/Gross Profit: -113.54
• Enterprise Value/Ebitda: -0.18
• 1Y Price Target: $6.00
• Price Target Upside: 137.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 43 Neutral
• Price Target: ―

Mural Oncology Plc's stock is weighed down by its financial challenges, including zero revenue and high cash burn, which significantly impact its overall score. Technical indicators suggest some positive momentum, but the stock faces resistance. Valuation remains unattractive due to unprofitability. However, upcoming clinical milestones and strategic focus on efficiency provide potential upside, reflected in the corporate events score.

Positive Factors

Future Data Opportunities

Topline data from cohort 2 of ARTISTRY-6 remains on-track for a potentially registrational readout evaluating nemvaleukin monotherapy in patients with mucosal melanoma.

Innovative Drug Mechanism

Nemvaleukin is a highly differentiated IL-2 fusion protein that blocks adverse events seen from this drug class, stops proliferation of immune dampening T cell types, and activates tumor killing NK and T cells.

Potential Regulatory Progress

MURA believes an objective response rate (ORR) of 20-25% would be a meaningful outcome and would support a discussion with FDA on a BLA submission for accelerated approval.

Negative Factors

Clinical Development Challenges

MURA announced its decision to discontinue clinical development of nemvaleukin.

Unmet Clinical Endpoints

A review of the topline data from ARTISTRY-6 cohort showed the primary endpoint was not achieved.

Workforce Reduction

The company will undertake a reduction in its employee workforce of ~90%.

Mural Oncology Plc Business Overview & Revenue Model

Company Description

Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

How the Company Makes Money

Mural Oncology Plc generates revenue primarily through the sale of its proprietary cancer therapies and treatments. The company engages in licensing agreements and collaborations with pharmaceutical companies and research institutions to enhance its product pipeline and expand market reach. Additionally, Mural Oncology may receive milestone payments and royalties from partnerships, contributing to its revenue. The company also invests in clinical trials and regulatory approvals to ensure the successful commercialization of its therapies, which in turn drives sales and profitability.

Mural Oncology Plc Financial Statement Overview

Summary

Mural Oncology Plc faces challenges typical of early-stage biotech firms, with zero revenue and high R&D expenses leading to continuous losses. The company maintains a strong cash position and low debt, which are positives, but the lack of revenue generation and high cash burn rate present significant financial risks.

Income Statement

Mural Oncology Plc has consistently reported zero revenue over the past years, indicating a lack of commercialization of its products. The company has incurred significant losses, with a net loss of $128.5 million in 2024. This reflects the high R&D costs typical in the biotechnology industry without offsetting revenue.

Balance Sheet

The company has a relatively healthy equity position with a stockholders' equity of $140.5 million as of 2024. However, it has a low debt-to-equity ratio due to minimal debt, which is a positive sign of low leverage. The high cash reserves provide a cushion, but the continuous net losses are concerning for long-term sustainability.

Cash Flow

Mural Oncology Plc has negative operating cash flow and free cash flow, indicating cash burn without incoming revenue. Despite this, the company raised significant capital in previous years, ensuring liquidity in the short term. However, the lack of cash flow generation from operations remains a significant risk.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-900.00K	0.00	-2.57M	-1.54M	-1.47M
	EBIT
-104.23M	-138.26M	-194.64M	-195.15M	-175.37M
	EBITDA
-101.56M	-125.00M	-192.72M	-183.38M	-173.89M
	Net Income Common Stockholders
-130.73M	-128.51M	-207.45M	-200.03M	-175.43M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
107.68M	144.38M	270.85M	-19.39M	-25.31M
	Total Assets
132.08M	169.39M	301.75M	33.75M	35.11M
	Total Debt
6.78M	8.02M	15.01M	19.39M	25.31M
	Net Debt
-99.90M	-107.44M	-255.84M	38.77M	50.61M
	Total Liabilities
24.19M	28.89M	37.93M	55.41M	52.99M
	Stockholders Equity
107.89M	140.50M	263.82M	-21.66M	-17.88M
Cash Flow		Free Cash Flow
-128.05M	-128.64M	-197.70M	-174.10M	-161.05M
	Operating Cash Flow
-128.00M	-128.54M	-194.25M	-168.59M	-156.67M
	Investing Cash Flow
127.20M	-25.33M	-3.45M	-5.51M	-4.38M
	Financing Cash Flow
224.00K	196.00K	468.81M	174.10M	161.05M

Mural Oncology Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.53
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MURA, the sentiment is Negative. The current price of 2.53 is below the 20-day moving average (MA) of 2.64, above the 50-day MA of 2.38, and below the 200-day MA of 3.22, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.49 is Neutral, neither overbought nor oversold. The STOCH value of 22.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MURA.

Mural Oncology Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	58 Neutral	$4.96B	18.48	-17.00%	7.20%	13.61%	-24.47%
MURA	43 Neutral	$44.21M	―	-76.27%	―	―	―
LSTA	43 Neutral	$21.15M	―	-56.49%	―	―	7.07%
EQ	41 Neutral	$13.79M	―	-88.32%	―	-19.76%	-13.20%
BCAB	35 Underperform	$27.02M	―	-246.21%	―	―	44.38%
ELEV	33 Underperform	$22.52M	―	-78.32%	―	―	47.73%
JUNS		$65.88M	―		―	―	―

Mural Oncology Plc Corporate Events

Mural Oncology Highlights 2024 Financial Results and Strategic Focus

On March 11, 2025, Mural Oncology announced its financial results for the fourth quarter and year-end 2024, highlighting a strategic focus on operational efficiency that extended their cash runway into Q1 2026. The company is preparing for significant clinical milestones in 2025, including interim data from the ARTISTRY-7 trial in ovarian cancer and top-line data from the ARTISTRY-6 trial in mucosal melanoma. These trials, involving their lead candidate nemvaleukin alfa, could impact Mural’s market positioning and offer potential value creation opportunities. Additionally, Mural expanded its pipeline with two new development candidates, MURA-8518 and MURA-7012, aimed at enhancing immune response and reducing toxicity.